Bio Rad Laboratories Stock Buy Hold or Sell Recommendation
| BIO Stock | USD 254.45 9.44 3.85% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Bio Rad Laboratories is 'Cautious Hold'. The recommendation algorithm takes into account all of Bio Rad's available fundamental, technical, and predictive indicators you will find on this site.
Check out Bio Rad Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Bio and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Bio |
Execute Bio Rad Buy or Sell Advice
The Bio recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Bio Rad Laboratories. Macroaxis does not own or have any residual interests in Bio Rad Laboratories or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Bio Rad's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Bio Rad Trading Alerts and Improvement Suggestions
| Bio Rad Laboratories generated a negative expected return over the last 90 days | |
| The company reported the last year's revenue of 2.57 B. Reported Net Loss for the year was (99.4 M) with profit before taxes, overhead, and interest of 1.38 B. | |
| Over 84.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Neurological Biomarkers Global Market Review 2020-2024 and Forecast to 2030, Featuring Analysis of PerkinElmer, Abbott Labs, Thermo Fisher Scientific, Banyan Biomarkers, Bio-Rad Labs More |
Bio Rad Returns Distribution Density
The distribution of Bio Rad's historical returns is an attempt to chart the uncertainty of Bio Rad's future price movements. The chart of the probability distribution of Bio Rad daily returns describes the distribution of returns around its average expected value. We use Bio Rad Laboratories price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Bio Rad returns is essential to provide solid investment advice for Bio Rad.
| Mean Return | -0.34 | Value At Risk | -4.12 | Potential Upside | 3.85 | Standard Deviation | 2.43 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Bio Rad historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Bio Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Bio Rad, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Bio Rad Laboratories back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-12-31 | 427.3 K | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 388.6 K | Millennium Management Llc | 2024-12-31 | 379.1 K | Geode Capital Management, Llc | 2024-12-31 | 322 K | Parnassus Investments Llc | 2024-12-31 | 310.9 K | Southeastern Asset Management Inc | 2024-12-31 | 308.5 K | Sei Investments Co | 2024-12-31 | 271.4 K | Bank Of New York Mellon Corp | 2024-12-31 | 267.3 K | Westfield Capital Management Company, L.p. | 2024-12-31 | 264.6 K | Blackrock Inc | 2024-12-31 | 2 M | Vanguard Group Inc | 2024-12-31 | 1.9 M |
Bio Rad Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (52.1M) | 46.1M | (158.8M) | (46.3M) | 8.5M | 8.9M | |
| Change In Cash | 4.5M | (196.0M) | (36.6M) | (30.2M) | 85.4M | 89.7M | |
| Free Cash Flow | 476.4M | 535.7M | 80.3M | 218.3M | 266.2M | 279.5M | |
| Depreciation | 138.1M | 133.8M | 137.3M | 192.4M | 151.6M | 88.3M | |
| Other Non Cash Items | (3.4B) | (3.7B) | 5.3B | 1.4B | 1.0B | 1.1B | |
| Capital Expenditures | 98.9M | 120.8M | 114.2M | 156.7M | 189M | 198.5M | |
| Net Income | 3.8B | 4.2B | (3.6B) | (637.3M) | (99.4M) | (94.4M) | |
| End Period Cash Flow | 667.1M | 471.1M | 434.5M | 404.4M | 489.8M | 293.4M | |
| Change To Netincome | (2.0B) | (3.5B) | (3.8B) | 5.3B | 4.7B | 5.0B | |
| Change Receivables | 31.7M | 21.5M | 35.3M | 68.2M | 78.4M | 82.3M | |
| Net Borrowings | (1.1M) | (426.9M) | (3.0M) | 1.2B | 1.4B | 1.4B | |
| Dividends Paid | 20.2M | 35.3B | 68.2B | 100.1B | 115.1B | 120.9B | |
| Investments | 119.6M | (538.2M) | (994.2M) | (110.5M) | (160.2M) | (168.2M) |
Bio Rad Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Bio Rad or Life Sciences Tools & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Bio Rad's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Bio stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.25 | |
β | Beta against Dow Jones | 0.97 | |
σ | Overall volatility | 2.35 | |
Ir | Information ratio | -0.1 |
Bio Rad Volatility Alert
Bio Rad Laboratories exhibits very low volatility with skewness of -0.58 and kurtosis of 2.63. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Bio Rad's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Bio Rad's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Bio Rad Fundamentals Vs Peers
Comparing Bio Rad's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Bio Rad's direct or indirect competition across all of the common fundamentals between Bio Rad and the related equities. This way, we can detect undervalued stocks with similar characteristics as Bio Rad or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Bio Rad's fundamental indicators could also be used in its relative valuation, which is a method of valuing Bio Rad by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Bio Rad to competition |
| Fundamentals | Bio Rad | Peer Average |
| Return On Equity | -0.24 | -0.31 |
| Return On Asset | 0.0155 | -0.14 |
| Profit Margin | (0.72) % | (1.27) % |
| Operating Margin | 0.09 % | (5.51) % |
| Current Valuation | 6.68 B | 16.62 B |
| Shares Outstanding | 22.94 M | 571.82 M |
| Shares Owned By Insiders | 15.56 % | 10.09 % |
| Shares Owned By Institutions | 84.48 % | 39.21 % |
| Number Of Shares Shorted | 862.65 K | 4.71 M |
| Price To Earning | 2.90 X | 28.72 X |
| Price To Book | 1.04 X | 9.51 X |
| Price To Sales | 2.82 X | 11.42 X |
| Revenue | 2.57 B | 9.43 B |
| Gross Profit | 1.38 B | 27.38 B |
| EBITDA | (2.14 B) | 3.9 B |
| Net Income | (99.4 M) | 570.98 M |
| Cash And Equivalents | 434.21 M | 2.7 B |
| Cash Per Share | 62.03 X | 5.01 X |
| Total Debt | 174.3 M | 5.32 B |
| Debt To Equity | 0.16 % | 48.70 % |
| Current Ratio | 5.50 X | 2.16 X |
| Book Value Per Share | 234.53 X | 1.93 K |
| Cash Flow From Operations | 455.2 M | 971.22 M |
| Short Ratio | 3.00 X | 4.00 X |
| Earnings Per Share | (65.37) X | 3.12 X |
| Price To Earnings To Growth | 1.19 X | 4.89 X |
| Target Price | 372.83 | |
| Number Of Employees | 7.7 K | 18.84 K |
| Beta | 0.99 | -0.15 |
| Market Capitalization | 7.24 B | 19.03 B |
| Total Asset | 9.36 B | 29.47 B |
| Retained Earnings | 7.42 B | 9.33 B |
| Working Capital | 2.56 B | 1.48 B |
Note: Disposition of 298 shares by Michael Crowley of Bio Rad at 4.6 subject to Rule 16b-3 [view details]
Bio Rad Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Bio . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Bio Rad Buy or Sell Advice
When is the right time to buy or sell Bio Rad Laboratories? Buying financial instruments such as Bio Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Bio Rad in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Soft Drinks Thematic Idea Now
Soft Drinks
Entities manufacturing and distributing non alcoholic beverages across different markets. The Soft Drinks theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Soft Drinks Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Bio Rad Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.412 | Earnings Share (65.37) | Revenue Per Share | Quarterly Revenue Growth (0.02) | Return On Assets |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.